Adherence to Adjuvant Endocrine Therapy in Breast Cancer Patients
Current Oncology · 21.01.2023 · 30 (2) · 1461-1472
DOI: 10.3390/curroncol30020112 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Oncology, online erschienen am 21.01.2023. Verfasst von Roberta Rosso und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gynecology and Obstetrics, Department of Surgical Sciences, School of Medicine, University of Turin, 10100 Turin, Italy. Hauptthemen laut MEDLINE: Breast Neoplasms. Die Arbeit wurde bisher 58-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Adjuvant endocrine therapy (AET) reduces breast cancer recurrence and mortality of women with hormone-receptor-positive tumors, but poor adherence remains a significant problem. The aim of this study was to analyze AET side effects and their impact on adherence to treatment.
Methods
A total of 373 breast cancer patients treated with AET filled out a specific questionnaire during their follow up visits at the Breast Unit of our Centre.
Results
Side effects were reported by 81% of patients, 84% of those taking tamoxifen and 80% of those taking aromatase inhibitors (AIs). The most common side effect in the tamoxifen group was hot flashes (55.6%), while in the AI group it was arthralgia (60.6%). The addition of GnRH agonists to both tamoxifen and AI significantly worsened all menopausal symptoms. Overall, 12% of patients definitively discontinued AET due to side effects, 6.4% during the first 5 years and 24% during extended therapy. Patients who had previously received chemotherapy or radiotherapy reported a significantly lower discontinuation rate.
Conclusions
AET side effects represent a significant problem in breast cancer survivors leading to irregular assumption and discontinuation of therapy. Adherence to AET may be improved by trustful patient–physician communication and a good-quality care network.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Gynecology and Obstetrics, Department of Surgical Sciences, School of Medicine, University of Turin, 10100 Turin, Italy.
ORCID-Profile: Valentina Elisabetta Bounous, Isabella Cipullo, Nicoletta Biglia
Zitieren
APA
Rosso, R., D'Alonzo, M., Bounous, V. E., Actis, S., Cipullo, I., Salerno, E., & Biglia, N. (2023). Adherence to Adjuvant Endocrine Therapy in Breast Cancer Patients. Current Oncology, 30(2), 1461-1472. https://doi.org/10.3390/curroncol30020112
Vancouver
Rosso R, D'Alonzo M, Bounous VE, Actis S, Cipullo I, Salerno E, et al. Adherence to Adjuvant Endocrine Therapy in Breast Cancer Patients. Current Oncology. 2023;30(2):1461-1472. doi:10.3390/curroncol30020112
BibTeX
@article{Rosso2023,
author = {Rosso, Roberta and D'Alonzo, Marta and Bounous, Valentina Elisabetta and Actis, Silvia and Cipullo, Isabella and Salerno, Elena and Biglia, Nicoletta},
title = {Adherence to Adjuvant Endocrine Therapy in Breast Cancer Patients},
journal = {Current Oncology},
year = {2023},
volume = {30},
number = {2},
pages = {1461--1472},
doi = {10.3390/curroncol30020112}
}
EUVIMED